



NDA 215256/S-006

## **SUPPLEMENT APPROVAL**

Novo Nordisk Inc.  
Attention: Stephanie DeChiaro  
Executive Director, Regulatory Affairs  
P.O. Box 846  
800 Scudders Mill Road  
Plainsboro, NJ 08536

Dear Ms. DeChiaro:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 24, 2022, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Wegovy (semaglutide) injection.

This “Changes Being Effected” supplemental new drug application provides for labeling changes as specified in the Agency’s Supplement Request Letter dated July 28, 2022.

### **APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling and with minor editorial revisions listed below and reflected in the enclosed labeling.

The issued date listed at the end of the Medication Guide has been updated to “08/2022.”

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (Medication Guide) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on August 24, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 215256/S-006.**” Approval of this submission by FDA is not required before the labeling is used.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christopher LaFleur, Regulatory Business Process Manager, at (240) 402 - 4724.

Sincerely,

*{See appended electronic signature page}*

Ramesh Raghavachari, Ph.D.  
Chief, Branch 1  
Division of Post-Marketing Activities I  
Office of Lifecycle Drug Products  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosures:

Medication Guide  
Carton and Container Labeling



Ramesh  
Raghavachari

Digitally signed by Ramesh Raghavachari  
Date: 2/14/2023 11:38:39PM  
GUID: 502d0913000029f375128b0de8c50020